This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA
-
P.J. Brooks Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Securing the Future of Open Source Software
Jack Cable and Remy DeCausemaker explore how CISA and CMS are tackling open source software (OSS) security in government.
4m listen -
How AI Will Continue to Advance Biometric Tech
At Identity Week, Arun Vemury discussed how error rates in facial recognition have dropped over the past decade thanks to machine learning.
12m listen -
TSA is Innovating Digital Identity Solutions with AI
At Identity Week, Jason Lim talked about the ways that digital identity is changing the way people travel securely.
10m listen -
The Security and UX Standards That Power Digital Identity Programs
Live from Identity Week, Ryan Galluzzo discusses the latest draft of NIST's Digital Identity Guidelines for the identity-proofing process.
18m listen